Protinhi Therapeutics is an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need via protease inhibition. With their proprietary technology platform, they are actively developing novel antiviral drugs that inhibit proteases and block viral replication. They aim for orally administered drugs able to treat in epidemic and pandemic situations.

Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently they focus on viral infectious diseases, including dengue fever, Zika, West Nile virus, chikungunya and corona virus. Their aim is to make those drugs available as new medication for patients in need of effective treatment.

For more information about Protinhi Therapeutics, visit their website.